The state of Utah currently has 41 active clinical trials seeking participants for Lung Cancer research studies. These trials are conducted in various cities, including Salt Lake City, Murray, Ogden and West Jordan.
A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors
Recruiting
The objective of this study is to assess safety and efficacy of BA3071 in solid tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
12/08/2023
Locations: University of Utah Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Solid Tumor, Adult, NSCLC, Urothelial Carcinoma, Gastric Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma, Cervical Carcinoma, Melanoma, Renal Cell Carcinoma, Carcinoma
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/28/2023
Locations: American Fork Hospital / Huntsman Intermountain Cancer Center, American Fork, Utah +5 locations
Conditions: Previously Treated Non-Small Cell Lung Cancer
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: American Fork Hospital / Huntsman Intermountain Cancer Center, American Fork, Utah +9 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Recruiting
A phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 as monotherapy in patients with NSCLC, HNSCC, GC/GEJ, ESCC, or other solid tumors and who have progressed after receiving prior therapy for advanced/metastatic disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/07/2023
Locations: START Mountain Region, West Valley City, Utah
Conditions: Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Recruiting
This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/04/2023
Locations: University of Utah Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation, Small Cell Lung Cancer, SCLC